Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.33 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.32 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12016623 | 0.86 | ALDH1A1 (0.39) | AHRTDP1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL2899421 | 0.83 | AHR (0.40) | AHRTDP1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL12016622 | 0.82 | TDP1 (0.40) | AHRTDP1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL12016620 | 0.82 | TDP1 (0.44) | AHRTDP1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL10299924 | 0.81 | CYP24A1 (0.36) | AHRTDP1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL12467754 | 0.81 | ALDH1A1 (0.36) | AHRTDP1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL10118389 | 0.81 | TBXAS1 (0.37) | AHRTDP1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL12016625 | 0.81 | TDP1 (0.42) | TDP1ALDH1A1TBXAS1EGLN3 | |
| SCHEMBL15464597 | 0.81 | ALDH1A1 (0.36) | AHRTDP1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL12016624 | 0.81 | ALDH1A1 (0.36) | AHRTDP1ALDH1A1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230220381-A1 | DNA-ENCODED FUNCTIONALIZED APTAMERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2023-07-13 | — | — | US | disclosed |
| US-20230220381-A1 | DNA-ENCODED FUNCTIONALIZED APTAMERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2023-07-13 | — | — | US | disclosed |
| US-20230220381-A1 | DNA-ENCODED FUNCTIONALIZED APTAMERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220381-A1 | DNA-ENCODED FUNCTIONALIZED APTAMERS | AS3MT, DNMT1, POLM | AHR 3663/4885TDP1 154/4885ALDH1A1 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.